8 results about "Prolonged release" patented technology

The present invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable vehicle and non-pungent derivatives of capsaicin, in their tautomeric forms and pharmaceutically acceptable salts, as the sole active ingredient, for use in the stimulation of the sphenopalatine ganglion and the enhancement of cerebral blood flow, to prevent or reduce brain injury resulting from decreased cerebral blood flow. The composition is administered via the oral transmucosal route, preferably in the form of a mucoadhesive tablet, and may be formulated for immediate or prolonged release, ensuring effective and tolerable absorption while avoiding the irritant effects associated with pungent capsaicin.

The invention relates to a pharmaceutical dosage form providing prolonged release of Tapentadol, wherein Tapentadol is present in form of a salt with phosphoric acid (orthophosphoric acid), preferably as dihydrogenphosphate salt. The dosage form according to the invention provides improved prolonged release properties, is particularly resistant against ethanol induced dose dumping, and beyond such resistance provides additional safety features with regard to concomitant use of ethanol, e.g. alcoholic beverages.

The invention relates to the technical field of medical instruments, in particular to a targeted balloon coating capable of prolonging the release period in a dynamic environment and a preparation method of the targeted balloon coating. The renaturable xerogel can be quickly rehydrated after being dried, and a temporary membrane is formed on the inner wall of a blood vessel to resist blood flow scouring. The exosome enhances the vascular endothelium targeting through RGD peptide targeted modification. The polydopamine-hyaluronic acid composite adhesion coating improves the flexibility and adhesion of the coating. Therefore, the drug retention rate within 1 hour after expansion is greater than or equal to 85%, and the vascular endothelium uptake efficiency of the RGD modified exosome is improved by 3 times.

A method is provided for providing sustained, controlled, or prolonged release of a compound of interest, such as a biomolecule or drug. The method includes incubating the compound of interest together with mercerized decellularized cellulose particles for a predetermined incubation time to enable the mercerized decellularized cellulose particles to absorb the compound of interest. The method then includes modifying the physical or chemical properties of the decellularized particles to induce, alter, enable, or influence the sustained, controlled, or prolonged release of the compound of interest. Mercerized decellularized particles and formulations for sustained, controlled, or prolonged release of the compound of interest are also provided.

The present invention relates to a method for obtaining prolonged release metformin minitablets, the minitablets obtainable by the method, and the use of these minitablets as a mono-therapeutic, or in combination with other active pharmaceuticals.

A composition including an amphiphilic compound capable of self-assembling into liquid crystalline particles and a statin for systemic administration via oral mucosa. A method of lowering blood cholesterol levels in a subject comprising administering the self-assembling liquid crystalline particles and statin via oral mucosa. Preferred dosage forms result in prolonged release of the statin.

A prolonged release oral solid pharmaceutical composition comprising: 0.1 to 30 % by weight of Betahistine or a pharmaceutically acceptable salt thereof; 1 to 90 % by weight of one or more release controlling polymer; optionally other suitable pharmaceutically acceptable excipients; wherein said release controlling polymer comprises carbomer and processes thereof. The prolonged release oral solid pharmaceutical composition exhibits dissolution profile according to which more than about 35% by weight of Betahistine is dissolved in 1 hour and a constant release over 24 hours.

The invention relates to extended release drug delivery systems for ophthalmic drugs and methods of use. Described herein are therapeutic compositions and methods of use for delivering a plurality of pharmaceutical substances within and around an eye, the therapeutic compositions comprising: a pharmaceutical substance that non-covalently interacts with one or more complexing agent particles to form pharmaceutical substance-complex particles mixed within a hydrophobic dispersion medium, the present invention relates to a multi-phase colloidal suspension that collectively forms a stable multi-phase colloidal suspension that is useful as a prolonged release drug delivery system for ocular drug delivery. Formulations of a drug substance in a multiphase colloidal suspension can be administered within the ocular nitrile and around the eye to produce sustained release of the drug substance within the ocular tissue at therapeutic levels for one or more months without the need for re-treatment.